RH-30

RH-30

Cat.No.: CSC-C0500

Species: Homo sapiens (Human)

Source: Bone Marrow Metastasis

Morphology: adherent epithelial-like cells growing as monolayer

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0500
Description
Established from the bone marrow metastasis of a 17-year-old man with undifferentiated (standard classification) or unclassified (Palmer classification) alveolar rhabdomyosarcoma; cells were described as carrying a p53 mutation, expressing high levels of both myogenin and myoD, and expressing the Pax3/FKHR fusion protein secondary to the t(2;13)(q35;q14) translocation
Species
Homo sapiens (Human)
Source
Bone Marrow Metastasis
Recommended Medium
90-95% RPMI-1640 + 5-10% h.i. FBS
Culture Properties
monolayer
Morphology
adherent epithelial-like cells growing as monolayer
Karyotype
Human flat moded hypotetraploid karyotype with 20% polyploidy - 78-87<4n>XX, -3, -4, -4, +5, +7, +7, -10, -10, -12, -12, -15, -19, +20, +20, +20, -21, +1-2mar, +0-4 dmin, add(1)(p11), del(5)(q13), add(16)(p13), del(16)(p13.2) - sideline with i(3q)
Disease
Alveolar Rhabdomyosarcoma
Quality Control
Mycoplasma: negative in microbiological culture, PCR assays
Immunology: cytokeratin -, desmin +, endothel -, EpCAM -, GFAP -, neurofilament -, vimentin +
Viruses: PCR: EBV -, HBV -, HCV -, HIV -, HTLV-I/II -, SMRV -
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 2 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
Rh30; RH30; Rh-30; RH30SJ; SJRH-30; SJRH30; SJ-RH30; SJ-Rh 30; SJRH 30; SJCRH30; RC13; RMS-13; RMS 13; RMS13
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The RH30 cell line was established from the bone marrow metastasis of a 17-year-old man with undifferentiated or unclassified alveolar rhabdomyosarcoma. RH30 cell line expresses the t(2;13) translocation and chromosomal analysis showed near-triploid chromosomes, between 51 and 87. This line also has amplification of the 12q13–q15 region involving CDK4 and surrounding loci, and a heterozygous mutation of the TP53 tumor suppressor.

Rh30(SJRH30) cell line is characterized by its ability to grow rapidly in a laboratory setting and its resemblance to the original tumor. The Rh30 cell line is used to study the biology of rhabdomyosarcoma and to test potential treatments for this type of cancer.

Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody–Drug Conjugate in Preclinical Osteosarcoma Models

Molecular Cancer Therapeutics | DOI | Paper |

Background

Osteosarcoma lacks validated surface targets for antibody–drug conjugates. This study used surfaceome profiling to identify CADM1 as highly expressed in osteosarcoma but low in normal tissues. A novel CADM1-targeting ADC was generated with the tesirine payload SG3249. In vitro, the ADC selectively killed CADM1-positive osteosarcoma, rhabdomyosarcoma, and neuroblastoma cells. In vivo, a single 3 mg/kg dose reduced tumor volume and extended event-free survival across six osteosarcoma patient-derived xenograft models, producing complete and partial responses. These preclinical results support further clinical development of CADM1-targeted ADCs for osteosarcoma and other CADM1-expressing pediatric solid tumors.

Key Findings

CADM1 was identified by integrated proteomic and transcriptomic surfaceome profiling as a high-confidence osteosarcoma surface antigen, with higher expression in osteosarcoma than normal tissues and many pediatric cancers. Immunohistochemistry confirmed CADM1 in 79% of patient osteosarcoma samples and all PDX models. The anti-CADM1 ADC used a human anti-CADM1 mAb (clone PTA021_A1) conjugated to tesirine/SG3249, with a drug-to-antibody ratio of 3.76. In vitro, the ADC showed selective cytotoxicity against CADM1-positive osteosarcoma, rhabdomyosarcoma, and neuroblastoma cell lines, but not CADM1-negative K562 or Ewing sarcoma cells. It internalized into osteosarcoma cells and produced a bystander killing effect. In six CADM1-expressing osteosarcoma PDX models, a single 3 mg/kg dose significantly extended event-free survival; responses included MCR in OS2, CR in OS1 and OS33, and PR in OS9, OS17, and OS31. A CD19 ADC control was largely inactive. These data support CADM1 as a promising immunotherapeutic target.

Contribution

Creative Bioarray supplied the RH30 rhabdomyosarcoma cell line (cat. #CSC-C0500) used for flow cytometry and cytotoxicity assays. This reagent enabled testing of the CADM1-targeting ADC beyond osteosarcoma and supported the finding that CADM1 is a potential target in other pediatric solid tumors.

Validation of CADM1 expression in osteosarcoma.
Fig. 1. Validation of CADM1 expression in osteosarcoma.

Reduced B7-H3 Expression by PAX3-FOXO1 Knockdown Inhibits Cellular Motility and Promotes Myogenic Differentiation in Alveolar Rhabdomyosarcoma

B7-H3 (also known as CD276) is associated with aggressive characteristics in various cancers. Meanwhile, in alveolar rhabdomyosarcoma (ARMS), PAX3-FOXO1 fusion protein is associated with increased aggressiveness and poor prognosis. In the present study, we explored the relationship between PAX3-FOXO1 and B7-H3 and the biological roles of B7-H3 in ARMS. Quantitative real time PCR and flow cytometry revealed that PAX3-FOXO1 knockdown downregulated B7-H3 expression in all the selected cell lines (Rh-30, Rh-41, and Rh-28), suggesting that PAX3-FOXO1 positively regulates B7-H3 expression (Fig. 1). Wound healing and transwell migration assays revealed that both PAX3-FOXO1 and B7-H3 were associated with cell migration. Furthermore, knockdown of PAX3-FOXO1 or B7-H3 induced myogenin expression in all cell lines (Fig. 2).

B7-H3 expression is downregulated by PAX3-FOXO1 knockdown in alveolar rhabdomyosarcomaFig. 2. Knockdown of PAX3-FOXO1 downregulates the expression of B7-H3 (Kanayama, Takuyo, et al. 2021).

PAX3-FOXO1 and B7-H3 negatively regulate myogenin expression and interfere with myogenic differentiationFig. 3. Knockdown of PAX3-FOXO1 and B7-H3 induces the expression of myogenin and may induce myoblast differentiation (Kanayama, Takuyo, et al. 2021).

A Rhabdomyosarcoma Spheroid Culture Model for In Vitro Evaluation of Hypericin-Based Photodynamic Therapy

Advanced stages of pediatric alveolar rhabdomyosarcoma (RMA) are associated with an unfavorable outcome at established therapeutic strategies, accentuating the need for novel treatment options. Photodynamic therapy (PDT) with hypericin (HYP) has shown strong cytotoxic effects in two-dimensional (2D) cell culture. In order to more accurately mimic in vivo tissue architecture and better predict pharmaceutical response, the aim of this study was to establish a spheroid culture model by which PDT efficacy could be assessed in a three-dimensional (3D) context. Compared to 2D cell culture, a higher treatment resistance was detected, which can be related to spheroid structure and mechanisms of intercellular communication, signal transduction, and gene expression.

Effects of hypericin (HYP)-based photodynamic therapy (PDT) on cell proliferation and apoptosisFig. 4. Evaluation of hypericin (HYP)-based photodynamic therapy (PDT) effects on apoptosis marker expression of RH-30 tumor spheroids (Hempfling, Laura, et al. 2022).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products